Tegoprazan-Amoxicillin Dual Therapy vs. Bismuth Quadruple Therapy for H. Pylori Infection (TATH-1)
Key facts
- Who runs it
- Zhang Xiaofeng,MD
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 370 people enrolled
- Started
- 1 Nov 2023
- Ended
- 31 Oct 2025
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Tegoprazan 50 mg, tablets, orally, qd
- Esomeprazole 20mg BID
- Tegoprazan 50 mg, tablets, orally, bid
- amoxicillin +clarithromycin+colloidal bismuth pectin BID
- amoxicillin 1000mg tid
- Record updated
- 16 January 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Patients aged ≥18 years with Hp-positive first sterilization were included in this study
- Before treatment, the existence of Helicobacter pylori can be confirmed by one or more of the following methods: rapid urease test, Hp culture, 13C urea breath test, 14C urea breath test and stool Hp antigen test
Who cannot take part
- previous eradication treatment of Helicobacter pylori
- surgery that may affect gastric acid secretion (upper gastrointestinal resection or vagotomy)
- acute upper gastrointestinal bleeding
- active gastric or duodenal ulcer
- penicillin/furazolidone allergy
- Zollinger-Ellison syndrome or other hypergastric acid secretion diseases
- acute gastric or duodenal mucosal lesions
- severe neurological, cardiovascular, pulmonary, liver,renal, metabolic,gastrointestinal, urological, etc
- Any fertile woman must use proper contraception
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Standard eradication therapies using proton pump inhibitors (PPIs) require double doses to achieve sufficient acid suppression, yet failure rates remain high due to antibiotic resistance. Tegoprazan, a P-CAB agent, inhibits gastric acid more effectively than PPIs. This study hypothesizes that Tegoprazan-based dual therapy can achieve superior or non-inferior eradication rates compared to standard quadruple therapy. The study evaluates the antibacterial effect of Tegoprazan combined with high-dose Amoxicillin in H. pylori-infected patients.
The 3 groups in the trial
- Tegoprazan 50mg QDTreatment being tested
Tegoprazan 50 mg once daily plus Amoxicillin 1000mg TID for up to 2 weeks
Treatment: Tegoprazan 50 mg, tablets, orally, qd and amoxicillin 1000mg tid
- Esomeprazole 20 mg BIDExisting treatment, for comparison
esomeprazole 20 mg, tablets, orally, bid given in combination with amoxicillin 1000mg,clarithromycin 500mg bid,colloidal bismuth pectin 200mg bid for up to 2 weeks. OR esomeprazole 20 mg, tablets, orally, bis in die given in combination with amoxicillin 750mg capsules, orally, quarter die for up to 2 weeks.
Treatment: Esomeprazole 20mg BID and amoxicillin +clarithromycin+colloidal bismuth pectin BID
- Tegoprazan 50 mg BIDTreatment being tested
Tegoprazan 50 mg twice daily plus Amoxicillin plus Amoxicillin 1000mg TID for up to 2 weeks
Treatment: Tegoprazan 50 mg, tablets, orally, bid and amoxicillin 1000mg tid
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Tegoprazan-Amoxicillin Dual Therapy Versus Esomeprazole-Based Bismuth Quadruple Therapy for First-Line Helicobacter Pylori Eradication: A Prospective, Randomized, Multicenter, Superiority Study (TATH-1)
- Record updated
- 16 January 2026